Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
Cochlear Feeling The Pinch
May 23 2013
Cochlear implant companies will launch new products at the EU conference this week. Brokers flag just how much of Cochlear’s market share is under pressure.
CSL Analysts Shrug Off Alzheimer’s Disappointment
May 10 2013
Brokers were not ascribing value to Alzheimer’s treatment potential anyway, so Baxter’s disappointing trial does not impact on analysts’ CSL recommendations.
Price Pressures Mask ResMed’s Strength
Apr 29 2013
ResMed posted strong sales growth in the March quarter but brokers remain preoccupied with the price pressures in the US health care system.
Brokers Stay Positive On Sirtex
Apr 08 2013
Growth in Sirtex’s key product, SIR-Spheres, may have ebbed a little but brokers don’t see this standing in the way of longer term potential.
QRxPharma Poised For Pain Relief
Mar 11 2013
Brokers expect a positive response to MoxDuo IR from the US Food and Drug Administration will spark a strong rise in an undervalued QRxPharma.
GI Dynamics: Opportunity In Diabetes Control
Mar 08 2013
As the population of diabetics increases alarmingly a company with a device to control the disease has the world at its feet.
Weekly Broker Wrap: The Strong Dollar, Sober Advertising And The Aldi Effect
Feb 18 2013
Japan is impacting on the Aussie, Pharma tops investor popularity, advertising spending stays modest and Aldi gives local supermarkets a headache.
Questions Mount Over Cochlear’s Top Status
Feb 06 2013
Cochlear may be at the top of its market but, after a lukewarm half year, brokers see some potential for the leader to be challenged.
No Stopping CSL
Jan 30 2013
The Chartist reports that aside from the odd expected pullback, the charts suggest CSL’s rally is not yet over.
Bionomics On Threshold Of Discovery
Jan 30 2013
Biotech stock Bionomics is undervalued as its therapeutics program has been enhanced with the acquisition of Eclipse, according to Bell Potter.
